Immunosuppressive therapy for renal transplantation in children and adolescents

NICE technology appraisals [TA99] Published date:

NICE has made the following recommendations about the use of immunosuppressive drugs in children and adolescents receiving kidney transplants:

Basiliximab and daclizumab
Doctors should consider using basiliximab or daclizumab for induction therapy. These drugs should only be used with a combination of other drugs that includes ciclosporin.

Tacrolimus
Tacrolimus is a calcineurin inhibitor and can be used instead of ciclosporin when a person needs a calcineurin inhibitor as part of their initial therapy or maintenance therapy.

Mycophenolate mofetil
Doctors should consider using mycophenolate mofetil as part of immunosuppressive treatment after kidney transplantation only when a person has to stop taking a calcineurin inhibitor, or has to take a lower dose.

Mycophenolate sodium
NICE does not recommend the use of mycophenolate sodium as part of immunosuppressive regimens for children or adolescents undergoing kidney transplantation.

Sirolimus
NICE does not recommend the use of sirolimus as part of immunosuppressive regimens for children or adolescents undergoing kidney transplantation, except when a patient has had to stop taking calcineurin inhibitors because of their side effects.

Get involved